Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
Koh, Siang-Boon
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. [electronic resource] - Cancer research 06 2018 - 3054-3066 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1538-7445
10.1158/0008-5472.CAN-17-3932 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Cell Cycle Proteins--antagonists & inhibitors
Cell Line, Tumor
Cell Proliferation--drug effects
Checkpoint Kinase 1--antagonists & inhibitors
DNA Damage--drug effects
DNA Replication--drug effects
Deoxycytidine--analogs & derivatives
Drug Synergism
Female
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Nuclear Proteins--antagonists & inhibitors
Protein-Tyrosine Kinases--antagonists & inhibitors
Xenograft Model Antitumor Assays--methods
Gemcitabine
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine. [electronic resource] - Cancer research 06 2018 - 3054-3066 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1538-7445
10.1158/0008-5472.CAN-17-3932 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Cell Cycle Proteins--antagonists & inhibitors
Cell Line, Tumor
Cell Proliferation--drug effects
Checkpoint Kinase 1--antagonists & inhibitors
DNA Damage--drug effects
DNA Replication--drug effects
Deoxycytidine--analogs & derivatives
Drug Synergism
Female
Humans
Mice
Mice, Inbred BALB C
Mice, Nude
Nuclear Proteins--antagonists & inhibitors
Protein-Tyrosine Kinases--antagonists & inhibitors
Xenograft Model Antitumor Assays--methods
Gemcitabine